Skip to main content
DIMERIX LIMITED logo

DIMERIX LIMITED — Investor Relations & Filings

Ticker · DXB ISIN · AU000000DXB7 ASX Professional, scientific and technical activities
Filings indexed 1,124 across all filing types
Latest filing 2017-01-24 Regulatory Filings
Country AU Australia
Listing ASX DXB

About DIMERIX LIMITED

https://dimerix.com/

Dimerix Limited focuses on the development of therapeutic treatments for inflammatory diseases, with a primary emphasis on kidney and respiratory conditions. The company utilizes its proprietary Receptor-Heteromer Investigation Technology (DMX-Technology) to identify and validate G protein-coupled receptor (GPCR) targets. Its lead candidate, DMX-200, is a chemokine receptor (CCR2) antagonist currently in Phase 3 clinical trials for the treatment of Focal Segmental Glomerulosclerosis (FSGS). The company is also advancing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD) and exploring applications for diabetic kidney disease. The core strategy involves targeting multiple signaling pathways simultaneously to address unmet medical needs in chronic inflammatory and fibrotic diseases.

Recent filings

Filing Released Lang Actions
Company Presentation 12 pages 1.5MB
Regulatory Filings
2017-01-24 English
Appendix 4C - quarterly 6 pages 792.3KB
Regulatory Filings
2017-01-22 English
Trading Halt 2 pages 658.4KB
Regulatory Filings
2017-01-22 English
Dimerix Receptor-HIT data presented by Takeda 2 pages 268.7KB
Regulatory Filings
2016-12-13 English
Recruitment of Part A of Phase 2 Trial of DMX-200 Completed 2 pages 199.5KB
Regulatory Filings
2016-12-05 English
Appointment of Chief Executive Officer 2 pages 129.4KB
Regulatory Filings
2016-11-06 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.